Glooko is transforming digital health by connecting people with diabetes and their healthcare professionals, enabling telehealth, clinical research, and improved collaboration. The company's software platforms empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers - bringing insights together in one place. Data is easily uploaded - remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice. Over 3 million users have benefited from diabetes data insights using Glooko's solutions, which are trusted by world leaders in diabetes care, and used in 27 countries across 20 languages.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/14 | $7,000,000 | Series A-1 |
Lifeforce Ventures Samsung Venture Investment Social+Capital Partnership Sundeep Madra Yogen Dalal | undisclosed |
| 03/16/21 | $30,000,000 | Series D |
Canaan Partners Georgian Partners Health Catalyst Capital  Insulet Mayo Clinic Novo Nordisk | undisclosed |
| 10/10/24 | $100,000,000 | Series F |
Canaan Partners Georgian Partners Health Catalyst Capital | undisclosed |
